ZA200902453B - PAI-1 binding modulators for the treatment of ocular disorders - Google Patents

PAI-1 binding modulators for the treatment of ocular disorders

Info

Publication number
ZA200902453B
ZA200902453B ZA200902453A ZA200902453A ZA200902453B ZA 200902453 B ZA200902453 B ZA 200902453B ZA 200902453 A ZA200902453 A ZA 200902453A ZA 200902453 A ZA200902453 A ZA 200902453A ZA 200902453 B ZA200902453 B ZA 200902453B
Authority
ZA
South Africa
Prior art keywords
pai
treatment
ocular disorders
binding modulators
modulators
Prior art date
Application number
ZA200902453A
Other languages
English (en)
Inventor
Debra Fleenor
Lok-Hou Pang
Abbot Clark
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of ZA200902453B publication Critical patent/ZA200902453B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200902453A 2006-10-31 2007-10-31 PAI-1 binding modulators for the treatment of ocular disorders ZA200902453B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86371506P 2006-10-31 2006-10-31

Publications (1)

Publication Number Publication Date
ZA200902453B true ZA200902453B (en) 2010-07-28

Family

ID=39345074

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200902453A ZA200902453B (en) 2006-10-31 2007-10-31 PAI-1 binding modulators for the treatment of ocular disorders

Country Status (11)

Country Link
US (2) US20080107644A1 (enExample)
EP (1) EP2077829A2 (enExample)
JP (1) JP2010508306A (enExample)
KR (1) KR20090082401A (enExample)
CN (1) CN101588798A (enExample)
AU (1) AU2007313684A1 (enExample)
CA (1) CA2666316A1 (enExample)
MX (1) MX2009004792A (enExample)
RU (1) RU2465898C2 (enExample)
WO (1) WO2008055205A2 (enExample)
ZA (1) ZA200902453B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100158897A1 (en) * 2006-10-31 2010-06-24 Alcon Research, Ltd. Pai-1 modulators for the treatment of ocular disorders
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
EP2790023B1 (en) 2011-11-15 2018-07-04 National University Corporation Hamamatsu University School of Medicine Therapeutic and diagnostic agent for early delivery or abortion using plasminogen activator inhibitor-1
US10946076B2 (en) 2013-02-13 2021-03-16 The Research Foundation For The State University Of New York Glaucoma treatment
US9820954B2 (en) * 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024121A1 (fr) * 1992-05-22 1993-12-09 Senju Pharmaceutical Co., Ltd. Medicament pour le glaucome
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
WO2000035439A1 (en) * 1998-12-11 2000-06-22 Bakulesh Mafatlal Khamar The process for manufacturing formulation of topical beta blockers with improved efficacy
CA2358400C (en) * 1999-01-05 2012-05-15 Nancy A. Noble Methods for treating conditions associated with the accumulation of excess extracellular matrix
CA2476761A1 (en) * 2002-02-19 2003-08-28 Vanderbilt University Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors
KR20040104566A (ko) * 2002-04-30 2004-12-10 알콘, 인코퍼레이티드 안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ｃｔｇｆ)의활성 및/또는 발현 조절, 저해, 또는 변조제

Also Published As

Publication number Publication date
EP2077829A2 (en) 2009-07-15
CA2666316A1 (en) 2008-05-08
MX2009004792A (es) 2009-05-21
WO2008055205A2 (en) 2008-05-08
CN101588798A (zh) 2009-11-25
JP2010508306A (ja) 2010-03-18
WO2008055205A3 (en) 2008-07-17
US20080107644A1 (en) 2008-05-08
AU2007313684A1 (en) 2008-05-08
KR20090082401A (ko) 2009-07-30
US20100260784A1 (en) 2010-10-14
RU2465898C2 (ru) 2012-11-10
RU2009120545A (ru) 2010-12-10

Similar Documents

Publication Publication Date Title
IL191283A (en) Compositions for treating eye irregularities
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL193747A0 (en) New therapeutic combinations for the treatment of depression
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
IL197001A0 (en) Combination treatment for metabolic disorders
IL195819A0 (en) Modulators of metabolism and the treatment of disorders related thereto
IL195851A0 (en) Modulators of metabolism and the treatment of disorders related thereto
EP1976377A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP1983972A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
IL195203A0 (en) Compounds for the treatment of metabolic disorders
ZA200805645B (en) Compounds for the treatment of metabolic disorders
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
ZA200902453B (en) PAI-1 binding modulators for the treatment of ocular disorders
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
IL195392A0 (en) Compounds for the treatment of metabolic disorders
IL192851A0 (en) Compounds for the treatment of metabolic disorders
IL192982A0 (en) Compounds for the treatment of metabolic disorders
HK1121947A (en) Gdf-9/bmp-15 modulators for the treatment of bone disorders
GB0608007D0 (en) Preparation for the treatment of burns
HK1121736A (en) Modulators of the h3 receptor useful for the treatment of disorders related thereto
HK1122813A (en) Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
GB0724947D0 (en) Composition for the treatment of psychiatric disorders